X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs AUROBINDO PHARMA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD AUROBINDO PHARMA BIOCON LTD/
AUROBINDO PHARMA
 
P/E (TTM) x 80.0 14.3 558.4% View Chart
P/BV x 7.5 3.7 204.7% View Chart
Dividend Yield % 0.2 0.4 38.8%  

Financials

 BIOCON LTD   AUROBINDO PHARMA
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
AUROBINDO PHARMA
Mar-17
BIOCON LTD/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,162895 129.8%   
Low Rs483622 77.6%   
Sales per share (Unadj.) Rs194.6254.6 76.4%  
Earnings per share (Unadj.) Rs34.439.3 87.6%  
Cash flow per share (Unadj.) Rs48.346.6 103.6%  
Dividends per share (Unadj.) Rs1.002.50 40.0%  
Dividend yield (eoy) %0.10.3 36.9%  
Book value per share (Unadj.) Rs241.9160.0 151.2%  
Shares outstanding (eoy) m200.00585.88 34.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.23.0 141.8%   
Avg P/E ratio x23.919.3 123.7%  
P/CF ratio (eoy) x17.016.3 104.6%  
Price / Book Value ratio x3.44.7 71.7%  
Dividend payout %2.96.4 45.7%   
Avg Mkt Cap Rs m164,440444,390 37.0%   
No. of employees `0009.214.0 66.0%   
Total wages/salary Rs m7,47017,678 42.3%   
Avg. sales/employee Rs Th4,213.910,667.8 39.5%   
Avg. wages/employee Rs Th809.01,264.3 64.0%   
Avg. net profit/employee Rs Th745.21,645.8 45.3%   
INCOME DATA
Net Sales Rs m38,911149,157 26.1%  
Other income Rs m1,5711,159 135.6%   
Total revenues Rs m40,482150,316 26.9%   
Gross profit Rs m9,79534,343 28.5%  
Depreciation Rs m2,7724,276 64.8%   
Interest Rs m260667 39.0%   
Profit before tax Rs m8,33430,558 27.3%   
Minority Interest Rs m16350 324.7%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6167,597 21.3%   
Profit after tax Rs m6,88123,012 29.9%  
Gross profit margin %25.223.0 109.3%  
Effective tax rate %19.424.9 78.0%   
Net profit margin %17.715.4 114.6%  
BALANCE SHEET DATA
Current assets Rs m40,47792,062 44.0%   
Current liabilities Rs m16,78366,223 25.3%   
Net working cap to sales %60.917.3 351.5%  
Current ratio x2.41.4 173.5%  
Inventory Days Days60106 56.2%  
Debtors Days Days8368 122.4%  
Net fixed assets Rs m45,07362,919 71.6%   
Share capital Rs m1,000586 170.7%   
"Free" reserves Rs m47,37793,133 50.9%   
Net worth Rs m48,37793,719 51.6%   
Long term debt Rs m21,0821,814 1,162.2%   
Total assets Rs m93,942162,494 57.8%  
Interest coverage x33.146.8 70.6%   
Debt to equity ratio x0.40 2,251.5%  
Sales to assets ratio x0.40.9 45.1%   
Return on assets %7.614.6 52.2%  
Return on equity %14.224.6 57.9%  
Return on capital %12.632.7 38.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,98875,838 17.1%   
Fx outflow Rs m7,89930,224 26.1%   
Net fx Rs m5,08945,613 11.2%   
CASH FLOW
From Operations Rs m6,40032,786 19.5%  
From Investments Rs m-4,985-17,870 27.9%  
From Financial Activity Rs m-1,775-19,153 9.3%  
Net Cashflow Rs m-473-4,239 11.2%  

Share Holding

Indian Promoters % 40.4 54.1 74.7%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 8.0 105.7%  
FIIs % 10.7 27.7 38.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.2 195.1%  
Shareholders   109,995 69,601 158.0%  
Pledged promoter(s) holding % 0.0 8.6 0.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   ALEMBIC PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare BIOCON LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Feb 16, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE BIOCON LTD WITH

MARKET STATS